164 related articles for article (PubMed ID: 36519392)
1. Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy.
Xie L; Chen C; Liang X; Xu J; Sun X; Sun K; Yang R; Tang X; Guo W
Orthop Surg; 2023 Mar; 15(3):829-838. PubMed ID: 36519392
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer.
Mitchell KG; Parra ER; Nelson DB; Zhang J; Wistuba II; Fujimoto J; Roth JA; Antonoff MB;
J Thorac Cardiovasc Surg; 2019 Sep; 158(3):911-919.e6. PubMed ID: 31235357
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
Parra ER; Villalobos P; Zhang J; Behrens C; Mino B; Swisher S; Sepesi B; Weissferdt A; Kalhor N; Heymach JV; Moran C; Zhang J; Lee J; Rodriguez-Canales J; Gibbons D; Wistuba II
J Thorac Oncol; 2018 Jun; 13(6):779-791. PubMed ID: 29526824
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer.
Lang C; Lantos A; Megyesfalvi Z; Egger F; Hoda MA; Mosleh B; Klikovits T; Oberndorfer F; Timelthaler G; Ferencz B; Fillinger J; Schwendenwein A; Querner AS; Boettiger K; Renyi-Vamos F; Hoetzenecker K; Laszlo V; Schelch K; Dome B
ESMO Open; 2022 Dec; 7(6):100631. PubMed ID: 36399951
[TBL] [Abstract][Full Text] [Related]
8. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
Thomas PL; Groves SM; Zhang YK; Li J; Gonzalez-Ericsson P; Sivagnanam S; Betts CB; Chen HC; Liu Q; Lowe C; Chen H; Boyd KL; Kopparapu PR; Yan Y; Coussens LM; Quaranta V; Tyson DR; Iams W; Lovly CM
J Thorac Oncol; 2021 Jul; 16(7):1211-1223. PubMed ID: 33839362
[TBL] [Abstract][Full Text] [Related]
9. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
10. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis.
Zhang L; Zhang B; Dou Z; Wu J; Iranmanesh Y; Jiang B; Sun C; Zhang J
Front Immunol; 2021; 12():582594. PubMed ID: 33815356
[No Abstract] [Full Text] [Related]
12. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y
Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971
[TBL] [Abstract][Full Text] [Related]
13. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.
Yang Z; Xu J; Li R; Gao Y; He J
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3055-3065. PubMed ID: 31522278
[TBL] [Abstract][Full Text] [Related]
15. Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets.
Marques RF; Moreno DA; da Silva L; Leal LF; de Paula FE; Santana I; Teixeira G; Saggioro F; Neder L; Junior CA; Mançano B; Reis RM
Front Immunol; 2023; 14():1062856. PubMed ID: 36825029
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
[TBL] [Abstract][Full Text] [Related]
17. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
[TBL] [Abstract][Full Text] [Related]
18. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
Scilla KA; Zandberg DP; Bentzen SM; Mainor C; Heath J; Ioffe OB; Cellini AL; Edelman MJ; Riedel DJ; Feliciano JL
Lung Cancer; 2018 Sep; 123():87-90. PubMed ID: 30089601
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.
Solorzano-Ibarra F; Alejandre-Gonzalez AG; Ortiz-Lazareno PC; Bastidas-Ramirez BE; Zepeda-Moreno A; Tellez-Bañuelos MC; Banu N; Carrillo-Garibaldi OJ; Chavira-Alvarado A; Bueno-Topete MR; Del Toro-Arreola S; Haramati J
Clin Exp Immunol; 2021 Apr; 204(1):78-95. PubMed ID: 33306195
[TBL] [Abstract][Full Text] [Related]
20. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
